These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7139632)

  • 1. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis.
    Nausieda PA; Weiner WJ; Kaplan LR; Weber S; Klawans HL
    Clin Neuropharmacol; 1982; 5(2):183-94. PubMed ID: 7139632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dream phenomena induced by chronic levodopa therapy.
    Sharf B; Moskovitz C; Lupton MD; Klawans HL
    J Neural Transm; 1978; 43(2):143-51. PubMed ID: 104005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric symptoms with initiation of carbidopa-levodopa treatment.
    Lin JT; Ziegler DK
    Neurology; 1976 Jul; 26(7):699-700. PubMed ID: 945518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: Psychosis in patient on bromocriptine and levodopa with carbidopa.
    Lipper S
    Lancet; 1976 Sep; 2(7985):571-2. PubMed ID: 60643
    [No Abstract]   [Full Text] [Related]  

  • 5. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease.
    Hoehn MM
    Acta Neurol Scand; 1985 Feb; 71(2):97-106. PubMed ID: 3984685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 7. Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease.
    Duggal HS; Singh I
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):583-4. PubMed ID: 18022304
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa-induced psychosis: a kindling phenomenon.
    Moskovitz C; Moses H; Klawans HL
    Am J Psychiatry; 1978 Jun; 135(6):669-75. PubMed ID: 655276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
    Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 11. Second interim report of the nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.
    Nakanishi T; Iwata M; Goto I; Kanazawa I; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1989; 29 Suppl 1():3-8. PubMed ID: 2714305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease.
    Rosenthal SH; Fenton ML; Harnett DS
    Gen Hosp Psychiatry; 1992 Jul; 14(4):285-6. PubMed ID: 1505751
    [No Abstract]   [Full Text] [Related]  

  • 13. L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine.
    Sandyk R
    J Clin Psychopharmacol; 1986 Jun; 6(3):194-5. PubMed ID: 3711372
    [No Abstract]   [Full Text] [Related]  

  • 14. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy: problems and practices.
    Muenter MD
    Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease, depression, and the on-off phenomenon.
    Friedenberg DL; Cummings JL
    Psychosomatics; 1989; 30(1):94-9. PubMed ID: 2913602
    [No Abstract]   [Full Text] [Related]  

  • 18. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 19. Parkinson disease. Individualizing therapy.
    Feldman RG; Lannon MC
    Hosp Pract (Off Ed); 1985 Jan; 20(1):80A-80E, 80I, 80M, passim. PubMed ID: 3917453
    [No Abstract]   [Full Text] [Related]  

  • 20. Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.
    Nakanishi T; Kanazawa I; Goto I; Iwata M; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1990; 30 Suppl 1():3-8. PubMed ID: 2178938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.